Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

‘More research’ needed on CBD oil - BVA
BVA said there is a lack of robust evidence to demonstrate the safety and efficacy of CBD in pets.
Small pilot study suggests it can reduce epileptic seizures 

The British Veterinary Association has said more research is needed on the potential benefits and risks of cannabidiol (CBD) before proper regulation is brought in.

This follows a new pilot study by Colorado State University, which found that CBD oil could reduce the frequency of seizures in dogs with epilepsy, when given alongside conventional treatment.

The small study of 16 dogs assessed the short-term effect of CBD on seizure frequency. Nine dogs were treated with CBD for 12 weeks, while seven received a placebo. All dogs continued to receive standard anticonvulsant drugs, including phenobarbital and potassium bromide.

Of the dogs who received CBD, 89 per cent saw a reduction in the number of seizures they experienced. Researchers said there was a significant correlation between the degree of seizure reduction and the amount of CBD concentration in the dog’s blood. The findings have been published in the Journal of the American Veterinary Medical Association.

Responding to the study, BVA said there is a lack of robust evidence to demonstrate the safety and efficacy of CBD in pets.

Junior vice president Daniella Dos Santos said: “The use of cannabidiol (CBD) to treat pets is a live issue in the veterinary profession. While research is ongoing to look into its efficacy and risks, there is currently a lack of sufficient robust evidence to demonstrate health benefits and safety of CBD use in pets.
 
“The veterinary medicines regulator has stated that any products containing CBD must be regulated as a medicine, supported by scientific evidence and rigorously tested. At present no CBD-based products have been granted veterinary marketing authorisation in the UK.”

Pet owners who are concerned about their pet’s health should speak to their local vet for professional advice on safe and effective treatments, she added.

The Colorado team are now working on further research to determine whether a higher dosage could reduce seizures by more than 50 per cent. The study, which launched in January last year, aims to enrol 60 dogs. 

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.